What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitnews2026-06-02T16:00:49+00:00June 2nd, 2026|Endpoints News|
Male contraception startup closes $92.5M Series B; Novartis bets on actiniumnews2026-06-02T14:43:48+00:00June 2nd, 2026|Endpoints News|
Travere pays Everest $112M upfront to grow rare kidney disease pipelinenews2026-06-02T13:55:55+00:00June 2nd, 2026|Endpoints News|
Legend Biotech shares first in vivo CAR-T data, its next act after Carvyktinews2026-06-02T13:31:07+00:00June 2nd, 2026|Endpoints News|
#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutnews2026-06-02T12:01:53+00:00June 2nd, 2026|Endpoints News|
Citing ‘dangerous deals,’ lawmakers propose China restrictionsnews2026-06-02T12:00:58+00:00June 2nd, 2026|Endpoints News|
#ASCO26: Roche details narrow failure of breast cancer pill trialnews2026-06-02T12:00:25+00:00June 2nd, 2026|Endpoints News|
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exitnews2026-06-02T11:21:08+00:00June 2nd, 2026|Endpoints News|
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitisnews2026-06-02T10:58:14+00:00June 2nd, 2026|Endpoints News|
Praxis sinks on late-stage study fail for seizure pill, halts second trialnews2026-06-02T10:31:09+00:00June 2nd, 2026|Endpoints News|
